GSK 3772701
Alternative Names: GSK-3772701Latest Information Update: 13 Jan 2023
At a glance
- Originator Unknown
- Developer GSK; Unknown
- Class Antimalarials
- Mechanism of Action Cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malaria
Most Recent Events
- 11 Nov 2022 Phase-I clinical trials in Malaria in United Kingdom (GlaxoSmithKline pipeline, November 2022)